Patents by Inventor Roshantha A. Chandraratna

Roshantha A. Chandraratna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of cancer with specific RXR agonists
    Patent number: 10039731
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: August 7, 2018
    Assignee: Io Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • Autoimmune disorder treatment using RXR agonists
    Patent number: 10034845
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: July 31, 2018
    Assignee: lo Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 10004709
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: June 26, 2018
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 10004708
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: June 26, 2018
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20180133179
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 17, 2018
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20180133183
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 17, 2018
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20180133180
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 17, 2018
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20180133182
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 17, 2018
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20180133181
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 17, 2018
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS
    Publication number: 20180116985
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 3, 2018
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES
    Publication number: 20180064670
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 8, 2018
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 9907768
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: March 6, 2018
    Assignee: IO THERAPEUTICS, INC.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 9877941
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: January 30, 2018
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20170354623
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Application
    Filed: June 12, 2017
    Publication date: December 14, 2017
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS
    Publication number: 20170281577
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Application
    Filed: June 21, 2017
    Publication date: October 5, 2017
    Inventor: Roshantha A. Chandraratna
  • TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS
    Publication number: 20170281576
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Application
    Filed: June 21, 2017
    Publication date: October 5, 2017
    Inventor: Roshantha A. Chandraratna
  • Treatment of cancer with specific RXR agonists
    Patent number: 9717702
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: August 1, 2017
    Assignee: IO Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • Treatment of cancer with specific RXR agonists
    Patent number: 9655872
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: May 23, 2017
    Assignee: IO Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES
    Publication number: 20170119714
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Application
    Filed: October 31, 2016
    Publication date: May 4, 2017
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES
    Publication number: 20170119713
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Application
    Filed: October 31, 2016
    Publication date: May 4, 2017
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders